• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Immunotherapy : Episode 7

Episode 7 - Immunotherapy: Where Is It At? Where Is It Headed?

Video

Panelists Daniel J. George, MD, and Jeffrey Weber, MD, PhD, believe that while immunotherapy is still relatively new, this therapy option will play a promising role in the future for the treatment of cancer.

Immunotherapy is the most exciting area in cancer research right now, declares Dr George.

Dr George credits the IMPACT trial as a pivotal trial that led to the approval of Provenge, the first cellular immunotherapy approved by the FDA for the treatment of metastatic prostate cancer, and elaborates on the PSA quartile trial. He explains how the benefits of trials, in terms of overall survival and long-term disease-free survival with checkpoint inhibitors, help immunotherapy gain credibility for the treatment of cancer.

Dr Weber continues by highlighting current key trials featured during the ASCO 2013 meetings, which include trials for PD-1 antibodies, ipilimumab, and new combinations of ipilimumab with granulocyte-macrophage colony-stimulating factors (GM-CSFs).

George hopes that the results of key trials will help change the population of patients who can be treated with immunotherapy, as well as help providers treat patients in a more precise manner.


Related Videos
Mila Felder, MD, FACEP
Fabiola, Molina, MD, MHS | Image Credit: Yale School of Medicine
James Robinson, PhD, MPH, University of California, Berkeley
James Robinson, PhD, MPH, University of California, Berkeley
Shauna Downs, PhD, MS | Image Credit: Rutgers School of Public Health
James Robinson, PhD, MPH, University of California, Berkeley
Carrie Kozlowski
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
James Robinson, PhD, MPH, University of California, Berkeley
Carrie Kozlowski
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.